NCT04932850View on ClinicalTrials.gov

Study to Evaluate the Safety and Concentrations of Monoclonal Antibody Against Virus That Causes COVID-19 Disease.

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 1, 2021

Primary Completion Date

October 20, 2021

Study Completion Date

October 20, 2021

Conditions
COVID-19 Virus Disease
Interventions
BIOLOGICAL

MAD0004J08

Human mAb 100 mg / 2.5 mL solution for injection

OTHER

Placebo

Placebo matching to MAD0004J08 2.5 mL solution for injection

Trial Locations (2)

37134

Crc - Verona, Verona

00149

Inmi 'L.Spallanzani' - Irccs, Rome

Sponsors

Collaborators (1)

Cross Research S.A.
All Listed Sponsors
collaborator

Cross Research S.A.

INDUSTRY

lead

Toscana Life Sciences Sviluppo s.r.l.

INDUSTRY

NCT04932850 - Study to Evaluate the Safety and Concentrations of Monoclonal Antibody Against Virus That Causes COVID-19 Disease. | Biotech Hunter | Biotech Hunter